AqueSys, Inc.: Series C $35M

Posted in I - Series C, Q - 2Q10, R - WEST, X - Device (Ophthalmology), XX - CA

AqueSys (Irvine, CA) a clinical-stage medical device company focused on implants for the treatment of glaucoma, closed a $25M Series C financing. Participants include Longitude Capital, Rho Ventures, Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.

Jun

2010

Altura Medical, Inc.: Series A $20M

Posted in I - Series A, Q - 2Q10, R - WEST, X - Device (Aneurysm), XX - CA

Altura Medical (San Clemente, CA) a development-stage medical device company focused on the treatment of abdominal aortic aneurysms, closed a $20M Series A financing. Participants include New Leaf Venture Partners, Advanced Technology Ventures and SV Life Sciences.

Jun

2010

Logical Therapeutics, Inc.: Series C $16.9M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - GI, X - Inflammation, X - NSAID, XX - MA

Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.

Apr

2010

Catabasis Pharmaceuticals, Inc.: Series A $39.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Inflammation, X - Metabolism, XX - MA

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Apr

2010

Juvaris BioTherapeutics, Inc.: Series B $12.5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, XX - CA

Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.

Feb

2010

Ophthotech Corp.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Oxagen, Ltd.: Series C $25.9M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Jan

2010

Entellus Medical, Inc.: Series D $30M

Posted in I - Series D, Q - 4Q09, R - MID WEST, X – Device (Sinusitis), XX - MN

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on the treatment for chronic sinusitis, closed a $30M Series D financing. Participants include Essex Woodlands Health Ventures, Split Rock Partners and SV Life Sciences.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Adimab, Inc.: Series D $8.2M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Antibody, XX - NH

Adimab (Lebanon, NH) a commercial-stage yeast-based antibody discovery and optimization platform, closed a $8.2M Series D financing. Participants include Google Ventures, OrbiMed, Borealis Ventures,Polaris Venture Partners and SV Life Sciences.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Lux Biosciences, Inc.: Series B $50M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...